| Literature DB >> 34805253 |
Worraprat Chaisuwan1,2, Yuthana Phimolsiripol2,3, Thanongsak Chaiyaso2,3, Charin Techapun2,3, Noppol Leksawasdi2,3, Kittisak Jantanasakulwong2,3, Pornchai Rachtanapun2,3, Sutee Wangtueai3,4, Sarana Rose Sommano3,5, SangGuan You6, Joe M Regenstein7, Francisco J Barba8, Phisit Seesuriyachan2,3.
Abstract
Viral infections may cause serious human diseases. For instance, the recent appearance of the novel virus, SARS-CoV-2, causing COVID-19, has spread globally and is a serious public health concern. The consumption of healthy, proper, functional, and nutrient-rich foods has an important role in enhancing an individual's immune system and preventing viral infections. Several polysaccharides from natural sources such as algae, bacteria, and fungi have been considered as generally recognized as safe (GRAS) by the US Food and Drug Administration. They are safe, low-toxicity, biodegradable, and have biological activities. In this review, the bioactive polysaccharides derived from various microorganisms, including bacteria, fungi, and algae were evaluated. Antiviral mechanisms of these polysaccharides were discussed. Finally, the potential use of microbial and algal polysaccharides as an antiviral and immune boosting strategy was addressed. The microbial polysaccharides exhibited several bioactivities, including antioxidant, anti-inflammatory, antimicrobial, antitumor, and immunomodulatory activities. Some microbes are able to produce sulfated polysaccharides, which are well-known to exert a board spectrum of biological activities, especially antiviral properties. Microbial polysaccharide can inhibit various viruses using different mechanisms. Furthermore, these microbial polysaccharides are also able to modulate immune responses to prevent and/or inhibit virus infections. There are many molecular factors influencing their bioactivities, e.g., functional groups, conformations, compositions, and molecular weight. At this stage of development, microbial polysaccharides will be used as adjuvants, nutrient supplements, and for drug delivery to prevent several virus infections, especially SARS-CoV-2 infection.Entities:
Keywords: COVID-19; SARS-CoV-2; antiviral activity; immunomodulation; sulfated polysaccharides
Year: 2021 PMID: 34805253 PMCID: PMC8602887 DOI: 10.3389/fnut.2021.772033
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Figure 1SARS-CoV-2 structure.
The microbial polysaccharides with antiviral activity.
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
|
| Acidic polysaccharide (CmAPS) | Human influenza A virus: A/H1N1, A/H2N2, A/H3N2 and A/H1N1 | Inhibited virus adsorption and virus-induced erythrocyte hemagglutination and hemolysis | ( |
|
| Sulfated polysaccharide | Human influenza virus H1-364 | Prevented virus adsorption and replication | ( |
|
| Sulfated exopolysaccharide (p-KG03) | Ecephalomyocarditis virus (EMCV) | Inhibited EMCV infection in HeLa cells | ( |
|
| Sulfated exopolysaccharide (p-KG03) | Influenza A virus | Inhibition of influenza virus replication | ( |
|
| Polysaccharide | HSV-1 | N/A | ( |
|
| Sulfated polysaccharide HC-b1 | HSV-1, including acyclovir-resistant strain and clinical strain | Inhibited virus absorption and penetration, and inhibited replication of HSV-1 in host cells | ( |
|
| Sulfated polysaccharide | HSV-2 | N/A | ( |
|
| Polysaccharide | Respiratory syncytial virus (RSV) | Inhibited RSV replication and induced IFN-α secretion | ( |
|
| LJ04 polysaccharide | Enterovirus 71 (EV71) | Inhibited viral proliferation, viral-induced apoptosis, and increased IFN-β expression | ( |
|
| Fucoidan | I-type influenza virus, adenovirus and parainfluenza virus I | N/A | ( |
|
| Naviculan | HSV-1, HSV-2, and Influenza A virus (H1N1) | Inhibited viral adsorption and penetration | ( |
|
| Polysaccharide | Herpes simplex virus type 1 and 2 (HSV-1 and HSV-2) | Inhibited virus adsorption | ( |
|
| i Polysaccharide | Varicella zoster virus (VZV) | i Polysaccharide may block different phases of viral replication cycle | ( |
| Cell-wall sulfated polysaccharide | HSV-1, HSV-2, and VZV | Inhibited virus adsorption and/or production of new virions in host cells | ( | |
| Polysaccharide | Murine leukemia virus (MuLV) and murine sarcoma virus (MuSV-124) | Inhibition of virus adsorption | ( | |
|
| Sulfated galactofucan (SJ-D-S-H) and glucuronomannan (Gn) | SARS-CoV-2 | Binding SARS-Cov-2 spike glycoprotein | ( |
|
| Polysaccharide SFP | Avian leukosis virus subgroup J (ALV-J) | Inhibited on virus adsorption phase by binding to virions and showed inhibitory effects both | ( |
|
| Sulfated polysaccharide SP-2a | HSV-1 | Inhibition of virus adsorption | ( |
|
| Fucoidan | HSV-2 | Inhibition of virus adsorption and/or virus penetration steps | ( |
|
| Sulfated polysaccharide | Japanese encephalitis virus (JEV) | Inhibited virus adsorption | ( |
|
| ||||
|
| Spirulan-like molecules | Human cytomegalovirus, HSV-1, human herpesvirus type 6 and HIV-1 | Inhibited the herpesviruses at an entry phase, but at a stage later than virus entry for HIV | ( |
|
| Calcium spirulan (Ca-SP) | HSV-1, human cytomegalovirus, measles virus, mumps virus, influenza A virus, and HIV-1 | Inhibited the penetration of virus into host cells | ( |
|
| Exopolysaccharide | Koi herpesvirus (KHV) | Inhibited the viral replication | ( |
| Exopolysaccharide | HSV-2 | Inhibited virus replication in human peripheral blood mononuclear cells (PBMC) | ( | |
| Exopolysaccharide | Intestinal viruses | Increased the expression of the antiviral factors MxA and RNase L | ( | |
| Exopolysaccharide | Transmissible Gastroenteritis Virus (TGEV) - Coronavirus | Inhibition effect that co-incubation with TGEV “Coronavirus” | ( | |
| Exopolysaccharide 26a | Human adenovirus type 5 (HAdV-5) | Suppressed the formation and release of HAdV-5 virions | ( | |
|
| Nostoflan | HSV-1, HSV-2,HCMV, and influenza A virus | Blocked virus adsorption and/or virus penetration steps | ( |
| Extracellular glycosaminoglycan and sulfated polysaccharide | HSV-1, Influenza A virus | N/A | ( | |
|
| ||||
|
| Sulfated | Newcastle disease virus | Inhibit the cellular infectivity (in chicken embryo fibroblast, CEF) of NDV in three ways (pre-, post- and simultaneous-adding polysaccharide) | ( |
|
| Polysaccharide BAS-F | Tobacco mosaic virus (TMV) | N/A | ( |
|
| Feline calicivirus (FCV) strain F9, feline herpesvirus 1, feline influenza virus H3N2 and H5N6, feline panleukopenia virus and feline infectious peritonitis virus | Antiviral effects on virus particles through blocking viral binding/absorption | ( | |
| Polysaccharide EP-AV1 and EP-AV2 | HSV-1, coxsackie virus B3 (CVB3) | N/A | ( | |
|
| Heteropolysaccharide GFP1 | Enterovirus 71 | Inhibited EV71 replication and suppressed viral VP1 protein expression and genomic RNA synthesis | ( |
|
| Lentinan | Infectious hematopoietic necrosis virus (IHNV) | Inhibited viral replication | ( |
|
| Acidic polysaccharide (APS) | Influenza A virus | Reduced virus titer the bronchoalveolar lavage fluid and the lung of mice infected with influenza A virus | ( |
N/A, Not available.
Figure 2The inhibition mechanism by directly inactivating virus.
Figure 3The inhibition mechanism of inhibiting virus adsorption and penetration.
Figure 4The inhibition mechanism by interfering with viral genome replication and protein synthesis.
Figure 5The modulation of the antiviral immune response by activation of macrophage and NK cell using the NF-κB and MAPK signaling pathways.
Some microbial polysaccharides from various sources with different characteristics and bioactivities.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Acidic polysaccharide (APS) |
| 576 | Containing: D-galactose, L-arabinose, D-xylose, L-rhamnose, and D-galacturonic acid; Linkage: Ara | Influenza A virus titres in the bronchoalveolar lavage fluid and the lung of mice were decreased. The APS increased the production of TNF-α, IFN-γ, and nitric oxide (NO) | ( |
| EPS0142 | 134 | Containing: glucose and galactose in an approximate molar ratio of 2.13:1.06 | ( | ||
| EPS-1 |
| 69.7 | Containing: mannose, glucose and galactose in the molar ratio of 8:1:11; Linkage: a backbone of 5-β-D-Gal | EPS-1 induced cytokines secretion, including IL-6, TNF-α, and IL-10, and up-regulated the related mRNA expression levels. | ( |
| FucoidanST-F |
| 19.8 | Containing: fucose (79.1 mol%) and galactose (19.9 mol%), and its sulfate content was 25.5%; Linkage: terminal, 1,4- and 1,3-linked fucose and terminal, 1,2- and 1,6-linked galactose residues | ST-F showed anti-HSV-2 activity with the IC50 of 18 μg·mL−1 | ( |
| Fucoidans SHAP-1 and SHAP-2 |
| 655 (SHAP-1) and 589 (SHAP-2) | Containing: fucose and galactose at a ratio of 3:1; sulfate content of 31.9%; Linkage: a backbone of α-(1 → 3)-linked L-Fuc | Both SHAP-1 and SHAP-2 showed antiviral activity against HSV-1 and HSV-2. The IC50 values of SHAP-1 and SHAP-2 against HSV-1 were 0.89 and 0.82 μg·mL−1, respectively, whereas both as low as 0.48 μg·mL−1 against HSV-2. | ( |
| GFP1 |
| 40.5 | Containing: glucose and fucose; a backbone of 1,6-β-β-glucan and a single 1,3-α-β-fucopyranosyl side-branching unit | GFP1 could inhibit EV71 replication in Vero cells and suppress viral VP1 protein expression | ( |
| Lentinan LNT-1 |
| 379 | Containing: glucose, mannose and galactose with the molar ratio of 19.26:1.20:1.00; Linkage: β-(1 → 3)-glucan backbone with -(1 → 6)-glucosyl side-branching units terminated by mannosyl and galactosyl residue | Lentinan directly inactivate IHNV and modulate immune responses by induce the expression of IFN-1 and IFN-γ, and reduce the expression of TNF-α, IL-2 and IL-11 in EPC cells | ( |
| Naviculan |
| 222 | Containing: fucose (26.6%), xylose (25.0%), galactose (20.7%), mannose (13.1%), and rhamnose (8.7%) | Naviculan had a broad antiviral spectrum against HSV-1, HSV-2, and Influenza A virus with the IC50 values of 14, 7.4, and 170 mg·mL−1, respectively. | ( |
| Nostoflan |
| 211 | → 4)-β-D-Glcp-(1 → 4)-D-Xylp-(1 → and → 4)-[β-D-GlcAp-(1 → 6)-]-β-D-Glcp-(1 → 4)-D-Galp-(1 → | Nostoflan showed broad antiviral activity against HSV-1, HSV-2, HCMV, and Influenza A virus | ( |
| Sulfated galactofucan (SJ-D-S-H) and glucuronomannan (Gn) |
| 13.7 (SJ-D-S-H) and 7.0 (Gn) | Both SJ-D-S-H and Gn showed good binding ability to SARS-CoV-2 spike glycoproteins. The IC50 values were 27 and 231 nM, respectively | ( | |
| Sulfated polysaccharide (CIF2) |
| 1,150 | Containing: mainly fucose (24.4%), glucose (21.3%), mannose (20.6%), galactose (16.7%), rhamnose (11.3%), and xylose (5.8%); Linkage: (1 → 3)-fucopyranose, (1 → 3) and (1 → 6)-galactopyranose residues | ( |